UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 19, 2016
AEGLEA BIOTHERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-37722 |
|
46-4312787 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
901 S. MoPac Expressway Barton Oaks Plaza One Suite 250 Austin, TX |
78746 |
|
(Address of principal executive offices) |
(Zip Code) |
(512) 942-2935
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02 Results of Operations and Financial Condition.
On May 19, 2016, Aeglea BioTherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2016. A copy of the press release is attached as Exhibit 99.1 to this report.
The information in this Item 2.02, including Exhibit 99.1 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit Number |
|
Description |
|
|
|
|
|
99.1 |
|
Press release issued by Aeglea BioTherapeutics, Inc. regarding its financial results for the three months ended March 31, 2016, dated May 19, 2016. |
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
AEGLEA BIOTHERAPEUTICS, INC. |
||
|
|
|
|
|
|
|
|
|
Date: May 19, 2016 |
|
|
|
By: |
|
/s/ Charles N. York II |
|
|
|
|
|
|
|
Charles N. York II |
|
|
|
|
|
|
|
Chief Financial Officer |
3
|
Exhibit Number |
|
Exhibit Title or Description |
|
|
|
|
|
99.1 |
|
Press release issued by Aeglea BioTherapeutics, Inc. regarding its financial results for the three months ended March 31, 2016, dated May 19, 2016. |
4